1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Zhejiang Zhenyuan Share Co., Ltd. Class A

Zhejiang Zhenyuan Share Co., Ltd. Class A

SSZSE:000705
6.67
CNY
+0.07
(+1.06%)
-0.08EPS
1.95BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.95
6.39
6.46
7.54
7.6
8.47
9.66
10.39
10.75
12.24
12.07
10.77
7.02
5.69
Basic EPS, GAAP
0.19
0.12
0.1
0.14
0.18
0.21
0.63
0.27
0.23
0.23
0.24
0.1
0.07
-0.08
Free Cash Flow per Basic Share
-0.39
-0.08
-0.43
0.23
0.04
-0.07
0.09
0.34
0.01
-0.37
-0.3
-0.74
-0.45
- -
Dividend per Share
0.03
0.01
- -
0.04
0.02
- -
0.03
0.06
0.07
0.06
0.06
0.07
0.08
0.08
Book Value per Share
3.5
3.63
3.8
3.87
4.1
4.42
5.06
5.21
5.55
5.76
5.91
5.87
5.91
5.8
Tangible Book Value per Share
3.39
3.51
3.69
3.72
3.86
4.18
4.89
5.05
5.39
5.41
5.57
5.54
5.61
5.5
Basic Weighted Avg Shares
339
326
335
323
339
338
336
331
336
339
340
347
324
334
Sales/Revenue/Turnover
2,018
2,081
2,165
2,440
2,578
2,858
3,243
3,440
3,612
4,145
4,106
3,741
2,276
1,899
Operating Margin (%)
3.79
2.34
1.55
2.16
2.37
2.84
2.62
2.47
2.33
2.68
2.36
1.36
0.63
-0.2
Depreciation Expense
26
29
42
47
54
57
54
54
89
92
101
98
103
- -
Net Income, GAAP
64
39
34
45
61
71
212
89
77
78
82
35
23
-26
Effective Tax Rate (%)
16.05
15.46
14.99
20.04
18.7
15.75
16.73
18.93
21.64
20.06
22.9
32.41
37.34
- -
Profit Margin (%)
3.19
1.88
1.55
1.86
2.37
2.48
6.52
2.6
2.14
1.88
1.99
0.93
1
-1.39
Working Capital
627
594
475
420
498
567
906
890
1,005
1,015
1,092
955
641
547
LT Debt
- -
- -
- -
- -
- -
- -
- -
76
48
53
55
165
164
97
Total Equity
1,178
1,223
1,283
1,314
1,390
1,498
1,712
1,762
1,872
1,947
1,999
1,962
1,975
1,938
Return on Invested Capital (%)
5.5
3.58
2.1
3.62
4.72
5.06
13.36
5.15
4.23
4.21
4.29
1.69
1.01
- -
Return on Capital (%)
5.61
3.25
2.71
3.48
4.34
4.83
12.93
4.79
4.01
3.87
3.93
1.66
1.1
- -
Return on Common Equity (%)
5.67
3.28
2.7
3.54
4.59
4.98
13.36
5.21
4.3
4.13
4.19
1.76
1.15
-1.34

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
118
122
218
LT Borrowings
136
147
77
LT Finance Leases
28
23
21
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
334
334
334
Market Capitalization
3,024
2,940
1,955

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,331
1,313
1,297
Cash, Cash Equivalents & STI
435
426
459
Accounts Receivable, Net
320
288
261
Inventories
452
489
484
Total Current Liabilities
690
717
750
Payables & Accruals
- -
- -
- -
ST Debt
118
122
218
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.5%
2.35%
0.68%
Free Cash Flow
-369.94%
-647.27%
-42.97%
Net Income, GAAP
12.66%
-20.01%
-34.66%
Sales/Revenue/Turnover
1.95%
-5.85%
-39.17%
Total Cash Common Dividend
489%
5.61%
13.22%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,045
914
893
889
3,741
2025
752
532
- -
496
2,276
2026
441
431
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.07
- -
-0.03
0.1
2025
0.11
0.06
- -
-0.1
0.07
2026
-0.07
0.03
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.01
0.07
2025
0.01
0.06
- -
0.01
0.08
2026
- -
0.01
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jun Chai
Full Time Employees
1,887
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 558 Yan'an East Road Shaoxing ZH China 312000
IPO Date
Apr 10, 1997
Website
zjzy.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Zhejiang Zhenyuan Share Co., Ltd. (000705.SZ) manufactures, wholesales and distributes pharmaceuticals primarily in China with some international operations. The company offers Chinese herbal medicines, herbal medicine slices, patent medicines; pharmaceutical raw materials, chemical preparations, antibiotics, biochemical drugs, biological products, medical devices, chemical reagents and glass instruments; pharmaceutical logistics and health services; as well as medicines, pre-packaged foods and dairy products including infant formula milk powder. It operates through pharmaceutical wholesale, manufacturing, distribution and health services segments targeting hospitals, pharmacies and consumers. Founded in 1993 and headquartered in Shaoxing, Zhejiang Province, China, the company traces its heritage to Zhenyuantang established in 1752 and listed on the Shenzhen Stock Exchange in 1997 as the first company recommended by the State Administration of Traditional Chinese Medicine. Recent developments include plans announced in September 2024 to publicly list its wholly-owned subsidiary Shaoxing Zhenyuan Pharmaceuticals Co., Ltd. via equity trading to optimize asset allocation and boost profitability in pharmaceutical wholesale; termination of a planned share issuance to specific investors; a change in controlling shareholder equity structure in early 2025 with Shaoxing State-owned Capital Operation Co., Ltd. acquiring stakes in Shaoxing Zhenyuan Health Industry Group under local state-owned enterprise reform; and an agreement in February 2025 to acquire an 11.26% stake in Zhejiang Zhenyuan Pharmaceutical Chain Co., Ltd. for CNY 37 million alongside a prior 10.89% minority interest purchase in July 2024 to consolidate its retail pharmacy operations.